STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #873 by analyst upside · 2026-06-27
PCVX
Vaxcyte, Inc.
Healthcare · Market Cap $8B · P/E 0x
ANALYST PRICE TARGET
+92.9%
implied upside to consensus target
Current Price $56.52
Consensus Target $109.0
Bull Target $163.0
Bear Target $67.0
Analysts Covering 9
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
7
Hold
1
Sell
0
52-Week Low $29.08
52-Week High $65.0
YTD Return +21.7%
FUNDAMENTALS
Market Cap $8B
P/E Ratio (TTM) N/A
Forward P/E -7.6x
EPS (TTM) $-7.25
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $29.08
52-Week High $65.0
Current Price $56.52
Bear Target $67.0
Bull Target $163.0
● Now $56.52 ● Target $109.0
TRADING DATA
Avg Volume 1.5M
YTD Return +21.7%
Analyst Count 9
Consensus Buy
Upside to Target +92.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Vaxcyte, Inc. (PCVX) is currently trading at $56.52 with a Wall Street consensus price target of $109.0, implying potential upside of 92.9% over the next 12 months. 9 analysts currently cover PCVX, with a consensus rating of Buy — 89% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $163.0, while the most cautious has a target of $67.0.

PCVX operates in the Healthcare sector with a market capitalisation of $8B. The stock is up 21.7% year-to-date and is currently trading near the upper end of its 52-week range of $29.08 – $65.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PCVX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG — Reiterated
Buy → Buy 2026-02-26 38% win rate (8 calls)
Guggenheim reit
Buy → Buy 2026-02-02 62% win rate (8 calls)
BTIG reit
Buy → Buy 2025-11-10 38% win rate (8 calls)
BTIG — Reiterated
Buy → Buy 2025-10-16 38% win rate (8 calls)
Goldman Sachs ● Initiated
Neutral 2025-09-12 Building track record
Cantor Fitzgerald ● Initiated
Overweight 2025-04-22 40% win rate (10 calls)
Needham reit
Buy → Buy 2025-04-08 20% win rate (5 calls)
Goldman Sachs — Reiterated
Buy → Buy 2025-04-01 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →